ABIVERTINIB

"Koma zuwa Pipeline

FUJOVEE (Abivertinib) (Cytokine Storm - STI 5656)

FUJOVEE (Abivertinib) ƙaramin ƙwayar ƙwayar cuta ce ta ƙarni na uku na tyrosine kinase inhibitor (TKI) wanda ke zaɓen duka nau'ikan mutant na mai karɓar haɓakar haɓakar epidermal (EGFR) da Bruton's tyrosine kinase (BTK)1

Yana hana maye gurbin ƙofa na EGFR; T790M, da kuma na gama-gari masu kunna maye gurbi (L858R, 19del).

Yana da ƙaramin aikin hanawa akan nau'in daji (WT) EGFR, yana ba da gudummawa ga bayanin martabar aminci da aka lura. Kyakkyawan haƙuri a allurai na baka har zuwa 600 MG kowace rana. 

Mataki na 2 NSCLC binciken da aka kammala tare da sakamako mai kyau da aka buga a cikin Binciken Ciwon Kankara na Clinical.2

  • Daga cikin amsawar 209 masu kimanta marasa lafiyar NSCLC waɗanda suka haɓaka juriya ga layin farko na TKIs:
  • 93.3% (n/N: 195/209) batutuwa sun sami raguwar ƙari a raunukan da aka yi niyya.
  • 57.4% (n/N: 120/209) batutuwa sun sami mafi kyawun amsa gabaɗaya (tabbatar + PR da ba a tabbatar ba).
  • 52.2% (n/N: 109/209) batutuwa da aka cimma sun tabbatar da PR.
  • 24.9 watanni OS.

Cikakken rahoton binciken asibiti da shirya kunshin don yin niyya don tattauna hanyar tsari tare da FDA a cikin 4Q22.

FDA ta ba da izinin IND a cikin Q2 2022 don nazarin mataki na 2 MAVERICK don magance ciwon daji na prostate mai jurewa (mCRPC). 

Hakanan ana gwada shi azaman yuwuwar magani don guguwar cytokine mai alaƙa da COVID-19 a cikin marasa lafiya na ICU.

1) Epidermal Growth Factor Receptor (EGFR), Bruton Tyrosine Kinase (BTK)
2) Sakamakon Nazari:  https://clincancerres.aacrjournals.org/content/early/2021/11/04/1078-0432.CCR-21-2595